NASDAQ : IONS
Ionis Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 43.52 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 7.23B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 7.23B |
| Enterprise Value | 7.32B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 166.18M |
| Shares Outstanding | 166.18M |
| Shares Change (YoY) | +4.49% |
| Shares Change (QoQ) | +0.33% |
| Owned by Insiders (%) | 0.78% |
| Owned by Institutions (%) | 110.06% |
| Float | 164.82M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.27 |
| Forward PS | 7.49 |
| PB Ratio | 16.39 |
| P/TBV Ratio | 16.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 8.37 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.89 |
| Quick Ratio | 6.85 |
| Debt / Equity | 4.98 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.64 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -105.50% |
| Return on Assets (ROA) | -12.42% |
| Return on Invested Capital (ROIC) | -72.03% |
| Return on Capital Employed (ROCE) | -22.19% |
| Weighted Average Cost of Capital (WACC) | 5.63% |
| Revenue Per Employee | $590,603 |
| Profits Per Employee | -$381,874 |
| Employee Count | 1,480 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 31.52 |
Taxes
| Measure | Value |
|---|
| Income Tax | 3.17M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.38 |
| 52-Week Price Change | -39.45% |
| 50-Day Moving Average | 49.02 |
| 200-Day Moving Average | 66.79 |
| Relative Strength Index (RSI) | 43.14 |
| Average Volume (20 Days) | 2,693,709 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 20.65M |
| Short Previous Month | 22.51M |
| Short % of Shares Out | 12.43% |
| Short % of Float | 12.53% |
| Short Ratio (days to cover) | 5.20 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 874.09M |
| Gross Profit | -60.60M |
| Operating Income | -594.35M |
| Pretax Income | -562.00M |
| Net Income | -565.17M |
| EBITDA | -579.49M |
| EBIT | -594.35M |
| Loss Per Share | -$3.46 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 2.10B |
| Total Debt | 2.19B |
| Net Cash | -86.67M |
| Net Cash Per Share | -$0.52 |
| Equity (Book Value) | 439.74M |
| Book Value Per Share | 2.65 |
| Working Capital | 2.18B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -496.43M |
| Capital Expenditures | -64.41M |
| Depreciation & Amortization | 14.87M |
| Net Borrowing | 69.67M |
| Free Cash Flow | -560.84M |
| FCF Per Share | -$3.37 |
Margins
| Measure | Value |
|---|
| Gross Margin | -6.93% |
| Operating Margin | -68.00% |
| Pretax Margin | -64.30% |
| Profit Margin | -64.66% |
| EBITDA Margin | -66.30% |
| EBIT Margin | -68.00% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.49% |
| Shareholder Yield | -4.49% |
| Earnings Yield | -7.96% |
| FCF Yield | -7.75% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $84.13 |
| Price Target Difference | 93.31% |
| Analyst Consensus | Buy |
| Analyst Count | 25 |
| Revenue Growth Forecast (3Y) | 26.50% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.83 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |